Fresenius SE & Co. (OTCMKTS:FSNUY) Short Interest Update

Key Points

• Short interest fell 40.6% to 114,842 shares as of July 31, representing approximately 0.0% of outstanding shares and only 0.2 days to cover.
• Fresenius reported quarterly revenue of $6.91 billion, exceeding estimates of $6.65 billion, while EPS of $0.24 slightly missed the $0.25 consensus forecast.
• Analyst sentiment remains positive: Morgan Stanley maintained an “overweight” rating, Deutsche Bank reaffirmed “buy,” and all three tracked analysts rate the stock a Buy.

Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report) saw a significant decrease in short interest in July. As of July 31st, there was short interest totaling 114,842 shares, a decrease of 40.6% from the July 15th total of 193,488 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily volume of 624,752 shares, the days-to-cover ratio is currently 0.2 days.

Fresenius SE & Co. Stock Performance

OTCMKTS FSNUY opened at $13.70 on Monday. The company has a market cap of $30.86 billion, a P/E ratio of 17.34 and a beta of 0.61. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.98 and a current ratio of 1.27. The business's 50 day moving average price is $12.17 and its 200-day moving average price is $12.74. Fresenius SE & Co. has a fifty-two week low of $10.33 and a fifty-two week high of $33.93.

Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.25 by ($0.01). The company had revenue of $6.91 billion during the quarter, compared to the consensus estimate of $6.65 billion. Fresenius SE & Co. had a return on equity of 10.33% and a net margin of 6.67%. Sell-side analysts predict that Fresenius SE & Co. will post 1.08 earnings per share for the current year.

Analysts Set New Price Targets

FSNUY has been the subject of a number of recent research reports. Morgan Stanley reissued an "overweight" rating on shares of Fresenius SE & Co. in a research note on Tuesday, July 21st. Deutsche Bank Aktiengesellschaft restated a "buy" rating on shares of Fresenius SE & Co. in a research report on Thursday, August 6th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Fresenius SE & Co. presently has an average rating of "Buy".

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world's leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source